
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Lestaurtinib
Introduction
Overview
Overview
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor undergoing research for the treatment of acute myelogenous leukemia (AML) and myeloproliferative disorders. It is an analog of staurosporine.
As of 2008, it is currently in Phase III clinical trials for AML and Phase II clinical trials for myeloproliferative disorders. [1]
It is being developed by Cephalon.
